US 12,121,545 B2
Composition for a fecal-derived sterilized postbiotic in anti-aging and neurotherapeutic applications
Andrea McBeth, Portland, OR (US); Piper Dobner, Milwaukie, OR (US); and Brice Thompson, Portland, OR (US)
Filed by THAENA INC., Vancouver, WA (US)
Filed on Jul. 31, 2023, as Appl. No. 18/228,222.
Claims priority of provisional application 63/394,016, filed on Aug. 1, 2022.
Prior Publication US 2024/0033299 A1, Feb. 1, 2024
Int. Cl. A61K 35/38 (2015.01)
CPC A61K 35/38 (2013.01) 19 Claims
 
1. A composition for a fecal derived sterilized postbiotic for anti-aging, the composition comprising:
a plurality of dose schedules, wherein a dose schedule of the plurality of dose schedules is selected as a function of a baseline biomarker of aging measurement to be administered to a subject, wherein the baseline biomarker of aging measurement comprises a biomarker of aging;
a plurality of biological macromolecules comprising at least an inorganic cofactor and a short chain fatty acid, wherein the short chain fatty acid comprises acetic acid, propionic acid, and butyric acid; and
a plurality of agents, wherein the plurality of agents is configured to regulate the biomarker of aging, wherein the plurality of agents comprises at least a co-emulsifying agent, wherein the at least a co-emulsifying agent comprises at least a surfactant.